All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @_life_with_kaitlyn on TikTok · 177s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @_life_with_kaitlyn's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Hi guys, okay, so week two in the books for compound summer blue side. I
  2. 0:07Already clean the top of here. So just kind of doing this as I'm talking to you guys about the week. Um, so
  3. 0:14Really good first week. I had
  4. 0:182.6 loss and this week I had
  5. 0:22This week is
  6. 0:233.4 pounds is my loss for the week. So bringing me to
  7. 0:272 over 6.4 as a total I did a weight loss journey going before I started taking common
  8. 0:34Some of the time and this is just in kind of like the kicker on top and let me tell you I
  9. 0:42was doing low-carb keto
  10. 0:46Before I got low carb keto in the past and being able to
  11. 0:51implement
  12. 0:53the some a glue tied with it has been kind of just a huge help just because I
  13. 1:01Don't think about food constantly like it's not something that I'm sitting here like oh my gosh
  14. 1:07I'm playing on my next meal counting down the hours and about the minutes until my next meal or my next
  15. 1:13constantly
  16. 1:16When my next meal is going to be quite frustrating
  17. 1:23And I weight loss journey to constantly be worried about that. So it's very nice to not have the worry this dress
  18. 1:31everything
  19. 1:32in that so this will be
  20. 1:34Third-shocked
  21. 1:36Like I said this past week loss is 3.4 pounds and I've got another again. I'm still on the 0.25
  22. 1:44Milligram or yeah 0.25 milligram with
  23. 1:48B12 and
  24. 1:5075 units with my pharmacy they changed their
  25. 1:55Just for something different see if it's 75 units for my prescription
  26. 2:01It is 0.25
  27. 2:04milligrams
  28. 2:07with
  29. 2:08B12 so I
  30. 2:12On this for this week and one more week
  31. 2:15I actually have my doctor appointment here in just a little bit to discuss
  32. 2:19What we are going to do for month two week five through eight and kind of see where we're from there
  33. 2:25So like I have said kind of before this is really nothing
  34. 2:29You kind of think it is and it's like crazy because it's like nothing you'll barely feel it
  35. 2:33Maybe feels like you're touching the end of a
  36. 2:38Safety pin maybe for a minute like just for like a second the initial prick other than that you don't feel anything
  37. 2:43It's awesome. If you are
  38. 2:46contemplating whether you want to do it or not just
  39. 2:49If you're thinking about it and thinking it can help you the food noise anything like that jump on board
  40. 2:54You won't be sorry

@_life_with_kaitlyn's compound semaglutide claims, fact-checked

_life_with_kaitlyn

TikTok creator

46.4K viewsWatch on TikTok

Quick answer

The creator is using compounded semaglutide at a 0.25 mg starting dose combined with B12, self-injecting at 75 units per her pharmacy's volume-based instructions, while following a low-carb diet concurrently. Her reported 6.4 pounds of total loss over two weeks likely reflects a combination of GLP-1-mediated appetite suppression and carbohydrate-restriction-driven water and glycogen loss, not medication effect alone. She is under provider supervision and has a scheduled clinical follow-up for dose escalation review, which represents a reasonable standard of care for this type of treatment.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @_life_with_kaitlyn's compound semaglutide claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@_life_with_kaitlyn's compound semaglutide claims, fact-checked" from _life_with_kaitlyn. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is using compounded semaglutide at a 0.

The reason this review is not generic is the source wording and the canonical claim label "glp1 week 2 weigh in wednesday 3 2 lbs lost this week on my comp." In this clip, the useful excerpt is: "Hi guys, okay, so week two in the books for compound summer blue side." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Early rapid weight loss on semaglutide combined with low-carb dieting is often partially glycogen and water depletion, not fat loss alone.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is using compounded semaglutide at a 0.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is using compounded semaglutide at a 0.25 mg starting dose combined with B12, self-injecting at 75 units per her pharmacy's volume-based instructions, while following a low-carb diet concurrently. Her reported 6.4 pounds of total loss over two weeks likely reflects a combination of GLP-1-mediated appetite suppression and carbohydrate-restriction-driven water and glycogen loss, not medication effect alone. She is under provider supervision and has a scheduled clinical follow-up for dose escalation review, which represents a reasonable standard of care for this type of treatment.
  • STEP 1 trial (Wilding et al., 2021, NEJM): average semaglutide weight loss was 14.9% over 68 weeks, not a predictor of week-by-week results at initiation doses.
  • Early rapid weight loss on semaglutide combined with low-carb dieting is often partially glycogen and water depletion, not fat loss alone.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • STEP 1 trial (Wilding et al., 2021, NEJM): average semaglutide weight loss was 14.9% over 68 weeks, not a predictor of week-by-week results at initiation doses.
  • Early rapid weight loss on semaglutide combined with low-carb dieting is often partially glycogen and water depletion, not fat loss alone.
  • GLP-1 receptors in the hypothalamus and brainstem drive appetite and food preoccupation reduction, the 'food noise' effect this creator describes is pharmacologically real (van Bloemendaal et al., 2023, Diabetes Care).
  • Compounded semaglutide is not FDA-approved and cannot be assumed equivalent to Wegovy or Ozempic in concentration or purity. The FDA issued quality and dosing error warnings for compounded versions in 2024.
  • No peer-reviewed evidence shows B12 addition to semaglutide improves weight loss outcomes. Its inclusion in compounded formulations is a commercial practice, not an evidence-based clinical protocol.
  • Semaglutide carries FDA black box warning language about thyroid C-cell tumor risk and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
  • Dose escalation decisions, like the week-five review she describes, should be made by a licensed prescriber based on tolerability and clinical response, not social media timelines.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @_life_with_kaitlyn actually say?

She's two weeks into compound semaglutide, still on a starting dose of 0.25 mg combined with B12, and claims 3.4 pounds lost in week two, with 6.4 pounds total across both weeks. She's also doing low-carb or keto alongside the medication.

The most specific claim she makes is about appetite suppression, describing what researchers call "food noise" reduction: "I don't think about food constantly" and noting she no longer counts down to meals. She also encourages viewers who are "thinking about it" to "jump on board," framing the injection as nearly painless and straightforward. She's transparent that she has a doctor's appointment to discuss dose escalation for weeks five through eight, which is worth noting as a point of responsible disclosure. She is not claiming this is a cure for anything, but the enthusiastic "you won't be sorry" closer is the kind of blanket endorsement that should come with context.

Does the science back this up?

On the weight loss numbers: 3.4 pounds in one week is plausible but sits at the high end of what clinical data predicts at a 0.25 mg starting dose. The food noise reduction claim, however, is well-supported by evidence.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide produced an average of about 14.9% body weight reduction over 68 weeks, but week-to-week results at initiation vary widely depending on baseline diet, water retention, and individual response. A 2022 study by Rubino et al. in JAMA also demonstrated that appetite suppression and reduced food preoccupation are among the earliest and most consistent effects reported by semaglutide users, often appearing before significant weight loss accumulates. The "food noise" mechanism is tied to GLP-1 receptor activity in the hypothalamus and brainstem, per a 2023 review by van Bloemendaal et al. in Diabetes Care. So her description of reduced meal obsession is not anecdote, it reflects documented pharmacology.

What did they get wrong (or right)?

She got the appetite suppression description right. Where things get murkier is the B12 combination and the dose unit framing.

She references "75 units" as her prescription measure, which is a volume-based description from a compounding pharmacy, not a standardized clinical dose. This matters because compounded semaglutide formulations are not FDA-approved, and their concentration, purity, and dosing equivalency to brand-name Wegovy or Ozempic cannot be assumed to be identical. The FDA has issued repeated warnings about compounded semaglutide quality concerns, including in a 2024 alert flagging dosing errors with compounded versions. The B12 addition is common in compounding, often marketed as an energy and tolerability booster, but there is no peer-reviewed evidence that B12 meaningfully enhances semaglutide's weight loss effect. She does not claim it does, to her credit, but the hashtag pairing of "b12" and "weightloss" implies a synergy that the data does not support. Her early weight loss also likely includes water weight from the concurrent low-carb diet, not purely a medication effect.

What should you actually know?

If you're considering compound semaglutide, the regulatory picture matters more than a week-two weigh-in, however relatable it is.

The FDA placed compounded semaglutide on its shortage list, which allowed compounding pharmacies to produce it legally, but that shortage status was officially ended for tirzepatide in 2024 and semaglutide policy has continued to shift. That means the legal landscape for compounded versions is actively changing. The STEP trials consistently show real, clinically meaningful weight loss with semaglutide, but the studies used FDA-approved formulations at verified doses. Compounded versions may work similarly for many people, but "may work similarly" is not the same as verified equivalency. Early weeks also tend to show faster scale movement due to glycogen depletion and water loss, particularly on a low-carb diet. Expecting 3-plus pounds every week is not realistic over the longer term. Anyone starting this medication should have a prescribing clinician monitoring for side effects including nausea, pancreatitis risk, and thyroid concerns, and dose escalation decisions should be made with a provider, not based on a TikTok weigh-in timeline.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

_life_with_kaitlyn · TikTok creator

46.4K views on this video

Week 2 Weigh in Wednesday! 3.2 lbs lost this week on my compound Semaglutide journey. A big thank you to Prestige Health and Aesthetics @thatnp_shana @ for getting me going! #semaglutide #tirzepatide

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about step 1 trial (wilding et al., 2021, nejm): average semaglutide?

STEP 1 trial (Wilding et al., 2021, NEJM): average semaglutide weight loss was 14.9% over 68 weeks, not a predictor of week-by-week results at initiation doses.

What does the video say about early rapid weight loss on semaglutide combined with low-carb dieting?

Early rapid weight loss on semaglutide combined with low-carb dieting is often partially glycogen and water depletion, not fat loss alone.

What does the video say about glp-1 receptors in the hypothalamus?

GLP-1 receptors in the hypothalamus and brainstem drive appetite and food preoccupation reduction, the 'food noise' effect this creator describes is pharmacologically real (van Bloemendaal et al., 2023, Diabetes Care).

What does the video say about compounded semaglutide?

Compounded semaglutide is not FDA-approved and cannot be assumed equivalent to Wegovy or Ozempic in concentration or purity. The FDA issued quality and dosing error warnings for compounded versions in 2024.

What does the video say about no peer-reviewed evidence shows b12 addition to semaglutide improves weight?

No peer-reviewed evidence shows B12 addition to semaglutide improves weight loss outcomes. Its inclusion in compounded formulations is a commercial practice, not an evidence-based clinical protocol.

What does the video say about semaglutide carries fda black box warning language about thyroid c-cell?

Semaglutide carries FDA black box warning language about thyroid C-cell tumor risk and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by _life_with_kaitlyn, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.